<DOC>
	<DOCNO>NCT00814632</DOCNO>
	<brief_summary>Vulvodynia characterize persistent vulvar pain , often occur upon touch pressure . The cause vulvodynia unknown presume involve many factor . Some factor may include altered immune response , infection , alter vaginal acid-base balance , allergic reaction psychosexual disorder . Women generally treat medication anti-histamines , anti-depressants anti-inflammatory , physical therapy minimize symptom . Other therapy vulvodynia include topical agent ( lidocaine , compound medication baclofen , gabapentin amitriptyline ) , oral medication ( gabapentin , pregabalin , calcium citrate ) , complementary therapy ( yoga , guide imagery , cognitive behavioral therapy ) low-oxalate diet , often ineffective . Surgery vulvodynia may helpful hard manage case , utilize last resort .</brief_summary>
	<brief_title>CC-10004 For The Treatment Of Vulvodynia</brief_title>
	<detailed_description>CC-10004 well-tolerated , selective PDE4 inhibitor demonstrate inhibitory effect inflammatory mediator development treatment inflammatory immune mediate condition . This open-label , one arm , phase II study William Beaumont Hospital . Twenty female subject age 18 old meeting criterion diagnosis vulvodynia vulvar vestibulitis ( vestibulodynia ) treat CC-10004 20mg orally twice day 12 weeks.The patient see total ten visit study coordinator .</detailed_description>
	<mesh_term>Vulvodynia</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Participant must understand voluntarily sign date appropriate Informed Consent document . 2 . Female ≥ 18 year age &lt; 70 year age . 3 . Participant must able adhere study visit schedule protocol requirement . 4 . Participant must vulvodyniavulvar pain 2 site test least 3 great 010 Likert scale . 5 . Subject report vulvar pain least 3 month prior enrollment . 6 . Participant currently take narcotic pelvic pain must stable regimen 3 month prior enrollment study . 7 . Females childbearing potential ( FCBP ) must negative urine pregnancy test screening/baseline ( Visit 1 ) . In addition , sexually active FCBP must agree use TWO follow adequate form contraception study medication : oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner . A FCBP must agree pregnancy test every 28 day study medication . 8 . Subject must meet follow laboratory criterion : Hemoglobin &gt; 9 g/dL Hematocrit ≥ 27 % White blood cell ( WBC ) count ≥ 3000 /mL ( ≥ 3.0 X 109/L ) &lt; 20,000/mL ( &lt; 20 X 109/L ) Neutrophils ≥ 1500 /mL ( ≥ 1.5 X 109/L ) Platelets ≥ 100,000 /mL ( ≥ 100 X 109/L ) Serum creatinine ≤ 1.5 mg/dL ( ≤ 132.6 μmol/L ) Total bilirubin £ 2.0 mg/dL Aspartate transaminase ( AST [ serum glutamic oxaloacetic transaminase , SGOT ] ) alanine transaminase ( ALT [ serum glutamate pyruvic transaminase , SGPT ] ) &lt; 1.5x upper limit normal ( ULN ) 1 . Pregnant lactating female 2 . History clinically significant cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic condition , major disease 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study 4 . History active Mycobacterium tuberculosis infection ( subspecies ) within 3 year prior screen visit . Infections occur &gt; 3 year prior entry must effectively treat . 5 . Positive TB skin test ( Mantoux test ) 6 . History incompletely treat latent Mycobacterium tuberculosis infection indicate positive positive Purified Protein Derivative [ PPD ] skin test vitro test [ TSPOT® . TB , QuantiFERON Gold® ] chest xray . 7 . Clinically significant abnormality chest xray ( CXR ) screening . 8 . Use investigational medication within 28 day prior randomization 5 halflives know ( whichever longer ) 9 . Any clinically significant abnormality 12lead ECG screen 10 . Positive human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C laboratory test result indicate active infection screening . 11 . History malignancy within previous 5 year ( except treat basalcell skin carcinoma ( ) and/or few 3 treat squamouscell skin carcinoma ) 12 . History vestibulectomy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>vulvodynia</keyword>
	<keyword>pelvic pain</keyword>
	<keyword>vulvar pain</keyword>
</DOC>